RapidAI Secures FDA Clearance for Rapid Aortic to Advance AI-Driven Aortic Disease Management
RapidAI has received U.S. FDA clearance for Aortic Management, a key component of its Rapid Aortic platform designed to improve how clinicians detect, measure, and monitor aortic disease. The company positions the system as part of its broader push into deep clinical AI, a category of tools intended to support decision-making across the full continuum of care rather than focusing solely on triage.
The cleared solution uses AI to characterize and quantify aortic abnormalities and generate automated 3D reconstructions of the aorta. It also tracks anatomical changes over time, giving radiologists and clinicians a consistent way to monitor disease progression. By analyzing any CT scan that includes the aorta, the platform can help identify aneurysms, dissections, and other pathology across the thoracic and abdominal regions. Automated guideline-based measurements and landmark metrics aim to reduce variability and support more efficient reporting.
RapidAI said these capabilities may ease the cognitive load on radiologists while helping surgical teams plan procedures and oversee long-term follow-up. Trissa Babrowski, MD, a vascular surgeon at the University of Chicago, said the system brings new clarity to aortic surveillance. “Rapid Aortic represents a significant advancement for aortic patient management,” she said. “With instant access to every textbook landmark and zonal maximum measurement, advanced visualizations, and robust longitudinal tracking for surveillance, Rapid Aortic empowers physicians to efficiently identify, confidently assess, and diligently monitor every aortic patient within their system.”
The platform is integrated into RapidAI’s cloud-based Rapid Edge infrastructure and connects with the company’s Navigator Pro radiology solution, as well as its mobile and web applications. These integrations allow clinicians to view and compare studies within existing PACS, EHR, and reporting workflows without disruption. The company emphasized the system’s continuity features, which maintain functionality even during local IT interruptions.
Karim Karti, CEO of RapidAI, said the new clearance underscores the company’s broader strategy to offer AI that supports comprehensive patient management. “This clearance reinforces the depth of our deep clinical AI platform and its growing impact across care teams,” he said. “Rapid Aortic exemplifies how we’re delivering intelligent, workflow-integrated tools that move beyond detection to full patient management.”
RapidAI will demonstrate the cleared solution at the 2025 VEITH Symposium, where the company plans to showcase how the technology may improve speed and consistency in aortic patient care.
